News | August 07, 2024
Gland Pharma posts 16% revenue growth in Q1 FY25
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
Narayana Hrudayalaya has reported total income of Rs. 1364.44 crores during the period ended June 30, 2024
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Strong topline growth driven by solid performance across key brands.
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
Subscribe To Our Newsletter & Stay Updated
